March 1, 2022 Deal value of US$ 1 billion with US$ 130 million upfront Novo Holdings co-created Syndesi Therapeutics in partnership with UCB Pharma and co-led the Series A financing Syndesi’s lead program SDI-118 to be accelerated by AbbVie to the benefit of patients suffering from cognitive impairment associated with a range of neurodegenerative and […]